pyrazines has been researched along with everolimus in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bendall, LJ; Bradstock, KF; Cisterne, A; Saunders, P; Weiss, J | 1 |
| He, XX; Huang, JJ; Huang, Y; Li, ZM; Lin, TY; Tian, Y; Xiao, J | 1 |
| Cavalli, F; Johnston, PB; Witzig, TE; Yuan, R | 1 |
| Nishi, S | 1 |
| Ramchandren, R | 1 |
| Azab, AK; Azab, F; Banwait, R; Flores, L; Ghobrial, IM; Jia, X; Maiso, P; Manier, S; Roccaro, AM; Sacco, A | 1 |
| Ogura, M | 1 |
| Bartlett, NL; Beck, JT; Cherfi, A; Cheung, W; Collins, RH; Fan, J; Fanning, SR; Goy, A; Johnston, PB; Kaminski, MS; Kaya, H; Klimovsky, J; Lister, J; O'Connor, OA; Popplewell, LL; Robeva, A; Tuscano, JM; Wang, M; Winter, JN | 1 |
| Choquet, S; Leblond, V; Nguyen, S; Souchet-Cömpain, L | 1 |
| Advani, RH; Anderson, KC; Barlogie, B; Dimopoulos, MA; García-Sanz, R; Gertz, MA; Ghobrial, IM; Gregory, SA; Kastritis, E; Kimby, E; Kyle, RA; Kyriakou, C; Landgren, O; Leblond, V; Leleu, X; Maloney, D; Merlini, G; Morel, P; Morra, E; Munshi, N; Owen, RG; Rummel, M; Terpos, E; Thomas, SK; Treon, SP | 1 |
| Barton, J; Bendell, JC; Burris, HA; Earwood, C; Hart, L; Infante, JR; Jones, SF; Lane, CM; Spigel, DR | 1 |
| Castillo, JJ; Ghobrial, IM; Treon, SP | 1 |
| Chirgwin, JM; Suvannasankha, A | 1 |
| François, RA; Hochwald, SN; Kaye, FJ; Maeng, K; Nawab, A; Zajac-Kaye, M | 1 |
| Treon, SP | 1 |
| Auriemma, RS; Colao, A; Cuomo, G; de Angelis, C; De Martino, MC; Hofland, LJ; Izzo, F; Napolitano, M; Negri, M; Pivonello, C; Pivonello, R; Provvisiero, DP; Simeoli, C | 1 |
| Anthony, LB; Carreira, VS; Chu, Z; Dahche, HM; Jiang, M; Koch, SE; Komurov, K; LaSance, K; Mercer, CA; Orr-Asman, MA; Plas, DR; Qi, X; Rubinstein, J; Thomas, HE; Worley, M | 1 |
7 review(s) available for pyrazines and everolimus
| Article | Year |
|---|---|
Targeted therapy in lymphoma.
Topics: Boronic Acids; Bortezomib; Everolimus; Humans; Lymphoma; Molecular Targeted Therapy; Pyrazines; Signal Transduction; Sirolimus; Survival Analysis | 2010 |
[Immunosuppressive agents in kidney transplantation].
Topics: Antibodies; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Cyclosporine; Everolimus; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Kidney Transplantation; Propylene Glycols; Pyrazines; Rituximab; Sirolimus; Sphingosine; T-Lymphocytes; Tacrolimus; TOR Serine-Threonine Kinases | 2011 |
Advances in the treatment of relapsed or refractory Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Brentuximab Vedotin; Drug Therapy; Everolimus; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Immunoconjugates; Immunotherapy; Lenalidomide; Protease Inhibitors; Pyrazines; Recurrence; Rituximab; Secondary Prevention; Sirolimus; Thalidomide | 2012 |
Current and future therapeutic approach for Waldenström's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Disease Progression; Everolimus; Forecasting; Guillain-Barre Syndrome; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Immunotherapy; Incidence; Lenalidomide; Myelin-Associated Glycoprotein; Protein Kinase Inhibitors; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Thalidomide; Transplantation, Autologous; Treatment Outcome; Waldenstrom Macroglobulinemia; Watchful Waiting | 2014 |
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consensus Development Conferences as Topic; Disease Progression; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2014 |
Biology, prognosis, and therapy of Waldenström Macroglobulinemia.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Everolimus; Humans; Piperidines; Prognosis; Proteasome Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Salvage Therapy; Sirolimus; Stem Cell Transplantation; Waldenstrom Macroglobulinemia | 2015 |
Role of bone-anabolic agents in the treatment of breast cancer bone metastases.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Everolimus; Female; Humans; Oligopeptides; Osteoblasts; Parathyroid Hormone; Proteasome Inhibitors; Pyrazines; Recombinant Fusion Proteins; Sirolimus; Thiophenes; Transforming Growth Factor beta | 2014 |
3 trial(s) available for pyrazines and everolimus
| Article | Year |
|---|---|
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat | 2012 |
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Pain; Pneumonia; Pyrazines; Salvage Therapy; Sirolimus; Treatment Outcome | 2014 |
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Everolimus; Female; Humans; Imidazoles; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Receptor, IGF Type 1; Sirolimus | 2015 |
7 other study(ies) available for pyrazines and everolimus
| Article | Year |
|---|---|
The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Everolimus; Humans; Immunosuppressive Agents; Leupeptins; Mice; Mice, Inbred NOD; Mice, SCID; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protease Inhibitors; Pyrazines; Radiation, Ionizing; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases; Whole-Body Irradiation | 2011 |
Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Everolimus; Humans; Jurkat Cells; Lymphoma, T-Cell; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrazines; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Vincristine | 2012 |
Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Bone Marrow; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cell Survival; Clinical Trials, Phase II as Topic; Drug Synergism; Everolimus; Humans; Mechanistic Target of Rapamycin Complex 1; MicroRNAs; Multiprotein Complexes; Pyrazines; Rituximab; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Tumor Cells, Cultured; Tumor Microenvironment; Waldenstrom Macroglobulinemia | 2012 |
Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Focal Adhesion Kinase 1; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neuroendocrine Tumors; Organic Chemicals; Pancreatic Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Pyrazines; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
How I treat Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2015 |
The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Combinations; Everolimus; Extracellular Signal-Regulated MAP Kinases; G1 Phase Cell Cycle Checkpoints; Hep G2 Cells; Humans; Imidazoles; Insulin; Liver Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; Receptor, IGF Type 1; Receptors, Somatomedin; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Messenger; Sirolimus; TOR Serine-Threonine Kinases | 2016 |
mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment.
Topics: Animals; Carcinoid Heart Disease; Cell Line, Tumor; Drug Resistance, Neoplasm; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Mice; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrazines; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |